|Publication number||USRE40493 E1|
|Application number||US 11/213,257|
|Publication date||Sep 9, 2008|
|Filing date||Aug 26, 2005|
|Priority date||May 27, 1999|
|Also published as||US6610317, US20020041896|
|Publication number||11213257, 213257, US RE40493 E1, US RE40493E1, US-E1-RE40493, USRE40493 E1, USRE40493E1|
|Inventors||Julie A. Straub, Howard Bernstein, Donald E. Chickering, III, Sarwat Khattak, Greg Randall|
|Original Assignee||Acusphere, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (58), Non-Patent Citations (99), Referenced by (6), Classifications (20), Legal Events (4)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This invention claims priority U.S. Ser. No. 60/186,310 filed Mar. 2, 2000, and is a continuation to PCT/US00/14578 filed May 25, 2000, which claims priority to U.S. Ser. No. 60/136,323 filed May 27, 1999, and U.S. Ser. No. 60/158,659 filed Oct. 8, 1999.
This invention generally relates to formulations of paclitaxel and more particularly to methods of making formulations of paclitaxel.
Paclitaxel is a natural product which has been shown to possess cytotoxic and antitumor activity. Indeed, paclitaxel may be among the most active single agent for ovarian and breast cancers. This compound is found in small concentrations in the Taxus brevifolia species such as the Pacific yew tree among other Taxus species. While having an unambiguous reputation of tremendous therapeutic potential, paclitaxel as a therapeutic agent has some patient related drawbacks. These stem, in part, from its extremely low solubility in water, which makes it difficult to provide in suitable dosage form. Because of paclitaxel's poor aqueous solubility, the current approved clinical formulation consists of a 6 mg/ml solution of paclitaxel in 50% polyoxyethylated castor oil (CREMOPHOR EL™) and 50% dehydrated alcohol. Am. J. Hosp. Pharm. 48:1520-24 (1991). In some instances, severe reactions, including hypersensitivity, occur in conjunction with the CREMOPHOR™ administered in conjunction with paclitaxel to compensate for its low water solubility. As a result of the incidence of hypersensitivity reactions to the commercial paclitaxel formulations and the potential for paclitaxel precipitation in the blood, the formulation must be infused over several hours. In addition, patients must be pretreated with steroids and antihistamines prior to the infusion.
In response to the hypersensitivity related to the CREMOPHOR™, the increasing recognition of paclitaxel's promise as an antineoplastic, and the undesirability of having to infuse the paclitaxel over several hours, there remains a need to develop improved formulations of the paclitaxel which can be administered as bolus injections.
It is therefore an object of the present invention to provide compositions of the paclitaxel without the solubilizing agent, CREMOPHOR™ which is present in the commercial formulation.
It is another object of the present invention to provide methods for producing the porous dry powder formulations of paclitaxel or docetaxol.
It is another object of the present invention to provide compositions providing enhanced dissolution of paclitaxel or docetaxol in a formulation suitable for administration by a variety of routes, including, but not limited to, parenteral, mucosal, oral, and topical administration, for local, regional, or systemic effect.
It is further object of the present invention to provide paclitaxel compositions for administration as a bolus injection instead of by infusion.
Paclitaxel is provided in a porous matrix form which forms nanoparticles and microparticles of paclitaxel when the matrix is contacted with an aqueous medium. The porous matrix with paclitaxel yields upon contact with an aqueous medium microparticles having a mean diameter between about 0.01 and 5 μm and a total surface area greater than about 0.5 m2/mL. The dry porous matrix is in a dry powder form having a TAP density less than or equal to 1.0 g/mL.
The porous matrices that contain the paclitaxel are preferably made using a process that includes (i) dissolving a paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the dry porous matrix of paclitaxel. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. If the pore forming agent is a liquid, the agent is emulsified with the paclitaxel solution. If the pore forming agent is a solid, the agent is (i) dissolved in the paclitaxel solution, (ii) dissolved in a solvent that is not miscible in the paclitaxel solvent and then emulsified with the paclitaxel solution, or (iii) suspended as solid particulates in the paclitaxel solution. Optionally, hydrophilic excipients, wetting agents, and/or tonicity agents may be added to the paclitaxel solvent, the pore forming agent solvent, or both. The solution, emulsion, or suspension of the pore forming agent in the paclitaxel solution is then processed to remove the paclitaxel solvent and the pore forming agent, as well as any pore forming agent solvent. In a preferred embodiment, spray drying, optionally followed by lyophilization, fluid bed drying, or vacuum drying, is used to remove the solvents and the pore forming agent.
An advantage of the formulations is that they can be administered as a bolus, when the paclitaxel normally must be infused to avoid toxicity and to avoid precipitation of the drug. By avoiding precipitation of paclitaxel in vivo, the formulations can also be administered intrarterially, intravenously, locally, intracranially, intrathecally, or directly into a tumor. An additional advantage is the formulations can be administered in reduced volumes.
In one embodiment, the matrix further includes a pegylated excipient with the paclitaxel. The pegylated excipient shields the paclitaxel from macrophage uptake, which prolong its half-life or enhance bioavailability of the paclitaxel.
In a preferred embodiment, the porous paclitaxel matrix is reconstituted with an aqueous medium and administered parenterally, such as intramuscularly, subcutaneously, or intravenously. Alternatively, the porous paclitaxel matrix can be further processed using standard techniques into tablets or capsules for oral administration or into rectal suppositories, delivered using a dry powder inhaler for pulmonary administration, or mixed/processed into a cream or ointment for topical administration.
Compositions of paclitaxel without the solubilizing agent, CREMOPHOR™, and which can be administered as a bolus are disclosed. The compositions are porous dry powders, which upon the addition of an aqueous medium form a suspension of paclitaxel nanoparticles and microparticles. Methods for producing the formulations of paclitaxel include using pore forming agents. The compositions may contain hydrophilic excipients, such as water soluble polymers and sugars, and wetting agents, such as surfactants.
I. Paclitaxel Matrix Compositions
The porous paclitaxel matrix is at least 1 to 95%, preferably at least about 10%, and more preferably between about 10 and 70%, paclitaxel by weight. The matrices also may contain hydrophilic excipients such as water soluble polymers or sugars, wetting agents such as surfactants, and tonicity agents.
The matrix must yield microparticles of paclitaxel, upon contact with an aqueous medium which preferably have a diameter between about 10 nm and 5 μm, more preferably between about 50 nm and 5 μm. The average total surface area of the microparticles contained within the porous matrix, which typically is in the form of a dry powder, is 0.5 m2/mL or greater. Total surface area values of the microparticles can be determined using standard particle sizing equipment and techniques.
The paclitaxel matrix must be sufficiently porous to yield microparticles, upon contact with an aqueous medium, having these parameters. Measurements useful in characterizing the porosity of the paclitaxel matrix are the bulk density or the transaxial pressure (“TAP”) density of the dry porous matrix (dry powder) and the total surface area (sum of internal and external surface area) of the dry porous matrix. The TAP density preferably is less than about 1.0 g/ml, more preferably less than 0.8 g/ml. This level of porosity of the matrix, characterized by density, provides sufficient surface area to enhance wetting of the dry porous matrix and enhance paclitaxel dissolution.
The total surface area (sum of internal and external surface area) of the porous matrix can be measured, for example, by BET surface area analysis. In some embodiments, the total surface area of the porous matrix preferably is greater than 0.1 m2/g, more preferably greater than or equal to 0.2 m2/g. This level of total surface area provides sufficient surface area to enhance wetting of the dry porous matrix and enhance drug dissolution.
As generally used in the description herein, “paclitaxel” includes taxanes and derivatives thereof, including paclitaxel and docetaxel, which have anticancer or antiangiogenic activity. Paclitaxel was specifically used in the examples which follow.
The matrices may contain hydrophilic excipients, such as water soluble polymers or sugars, which can serve as bulking agents or as wetting agents, wetting agents such as surfactants or sugars, and tonicity agents. Upon contact with an aqueous medium, water penetrates through the highly porous matrix to dissolve the water soluble excipients in the matrix. A suspension of paclitaxel particles in the aqueous medium remains. The total surface area of the resultant low aqueous solubility paclitaxel microparticles is increased relative to the unprocessed paclitaxel and the dissolution rate of the paclitaxel is increased.
One of skill in the art can select appropriate excipients for use in the paclitaxel matrix compositions, considering a variety of factors, such as the paclitaxel to be administered, the route of administration, the dosage, and the preferred dissolution rate. For example, the excipients can function as bulking agents, release-modifiers, wetting agents, tonicity agents, or combinations thereof. Preferred excipients include hydrophilic polymers, wetting agents, and sugars. The amount of excipient in the paclitaxel matrix is less than about 95%, more preferably less than about 80%, by weight of the paclitaxel matrix.
The hydrophilic excipients, wetting agents, and tonicity agents may be added to the paclitaxel solution, the pore forming agent, or both, during production of the matrix.
(i) Hydrophilic Polymers
The polymers that can be used in the paclitaxel matrices described herein include both synthetic and natural polymers, either non-biodegradable or biodegradable. Representative synthetic polymers include polyethylene glycol (“PEG”), polyvinyl pyrrolidone, polymethacrylates, polylysine, poloxamers, polyvinyl alcohol, polyacrylic acid, polyethylene oxide, and polyethyoxazoline. Representative natural polymers include albumin, alginate, gelatin, acacia, chitosan, cellulose dextran, ficoll, starch, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxy-propylmethyl cellulose, hyaluronic acid, carboxyethyl cellulose, carboxymethyl cellulose, deacetylated chitosan, dextran sulfate, and derivatives thereof. Preferred hydrophilic polymers include PEG, polyvinyl pyrrolidone, poloxamers, hydroxypropyl cellulose, and hydroxyethyl cellulose.
The hydrophilic polymer selected for use in a particular paclitaxel matrix formulation is based on a variety of factors, such as the polymer molecular weight, polymer hydrophilicity, and polymer inherent viscosity. The hydrophilic polymer can be used as a bulking agent or as a wetting agent.
Representative sugars that can be used in the paclitaxel matrices include mannitol, sorbitol, xylitol, glucitol, ducitol, inositiol, arabinitol, arabitol, galactitol, iditol, allitol, fructose, sorbose, glucose, xylose, trehalose, allose, dextrose, altrose, gulose, idose, galactose, talose, ribose, arabinose, xylose, lyxose, sucrose, maltose, lactose, lactulose, fucose, rhamnose, melezitose, maltotriose, and raffinose. Preferred sugars include mannitol, lactose, sucrose, sorbitol, trehalose, glucose, and are adjusted to provide osmolality if administered parenterally or to provide wetting of the porous paclitaxel matrix or the paclitaxel microparticles within the matrix.
(iii) Wetting Agents
Wetting agents can be used to facilitate water ingress into the matrix and wetting of the paclitaxel particles in order to facilitate dissolution.
Representative examples of wetting agents include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., TWEEN™s), polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxy propylcellulose, hydroxypropylmethylcellulose phthlate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, and polyvinylpyrrolidone (PVP). Tyloxapol (a nonionic liquid polymer of the alkyl aryl polyether alcohol type, also known as superinone or triton) is another useful wetting agent. Most of these wetting agents are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 1986).
Preferred wetting agents include polyvinylpyrrolidone, polyethylene glycol, tyloxapol, poloxamers such as PLURONIC™ F68, F127, and F108, which are block copolymers of ethylene oxide and propylene oxide, and polyxamines such as TETRONIC™ 908 (also known as POLOXAMINE™ 908), which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (available from BASF), dextran, lecithin, dialkylesters of sodium sulfosuccinic acid such as AEROSOL™ OT, which is a dioctyl ester of sodium sulfosuccinic acid (available from American Cyanimid), DUPONOL™ P, which is a sodium lauryl sulfate (available from DuPont), TRITON™ X-200, which is an alkyl aryl polyether sulfonate (available from Rohm and Haas), TWEEN™ 20 (polysorbate 20)and TWEEN™ 80 (polysorbate 80), which are polyoxyethylene sorbitan fatty acid esters (available from ICI Specialty Chemicals), Carbowax 3550 and 934, which are polyethylene glycols (available from Union Carbide), CRODESTA™, which is a mixture of sucrose stearate and sucrose distearate, and CRODESTA™ SL-40 (both available from Croda Inc.), and SA90HCO, which is C18H37CH2(CON(CH3)CH2(CHOH)4CH2OH)2.
Wetting agents which have been found to be particularly useful include TETRONIC™ CRODESTA™ 908, the TWEENS™, PLURONIC™ F-68 and polyvinylpyrrolidone. Other useful wetting agents include decanoyl-N-methylglucamide; n-decyl-β-D-glucopyranoside; n-decyl-β-D-maltopyranoside; n-dodecyl-β-D-glucopyranoside; n-dodecyl β-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-β-D-glucopyranoside; n-heptyl-β-D-thioglucoside; n-hexyl-β-D-glucopyranoside; nonanoyl-N-methylglucamide; n-noyl-β-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-β-D-glucopyranoside; and octyl-β-D-thioglucopyranoside. Another preferred wetting agent is P-isononylphenoxypoly(glycidol), also known as OLIN™-10G or Surfactant 10-G (commercially available as 10G from Olin Chemicals). Two or more wetting agents can be used in combination.
(iv) Tonicity or Osmolality Agents
The porous paclitaxel matrices may include one or more tonicity agents, such as salts (e.g., as sodium chloride or potassium chloride) or sugars (such as mannitol, dextrose, sucrose, or trehalose) to adjust a hypotonic solution of a paclitaxel to isotonic so that the paclitaxel, when in solution, is physiologically compatible with the cells of the body tissue of the patient. The type and amount of tonicity agent can be selected by one of skill in the art using known techniques.
(v) Pegylated Excipients
In one embodiment, the matrix further includes a pegylated excipient. Such pegylated excipients include, but are not limited to, pegylated phospholipids, pegylated proteins, pegylated peptides, pegylated sugars, pegylated polysaccharides, pegylated block co-polymers with of the blocks being PEG, and pegylated hydrophobic compounds such as pegylated cholesterol. The pegylated excipient beneficially envelops or shields the paclitaxel from macrophage uptake, which prolongs its half-life or enhances bioavailability of the paclitaxel.
Representative examples of pegylated phospholipids include 1,2-diacyl-sn-glycero-3-phosphoethanolamine-N-[Poly(ethyleneglycol) 2000] (“PEG 2000 PE”) and 1,2-diacyl-sn-glycero-3-phosphoethanolamine-N-[Poly (ethylene glycol) 5000] (“PEG 5000 PE”), where the acyl group is selected, for example, from dimyristoyl, dipalmitoyl, distearoyl, diolcoyl, and 1-palmitoyl-2-oleoyl.
Other polyalkyleneoxides can be used in place of the polyethylene glycol.
II. Volatile Solvents
The choice of solvent depends on the paclitaxel. In a preferred embodiment, the solvent is an organic solvent that is volatile, has a relatively low boiling point, or can be removed under vacuum, and which is acceptable for administration to humans in trace amounts. Representative solvents include acetic acid, acetaldehyde dimethyl acetal, acetone, acetonitrile, chloroform, chlorofluorocarbons, dichloromethane, dipropyl ethyl, diisopropyl ether, N,N-dimethylformamide (DMF), formamide, demethyl sulfoxide (DMSO), dioxane, ethanol, ethyl acetate, ethyl formate, ethyl vinyl ether, methyl ethyl ketone (MEK), glycerol, heptane, hexane, isopropanol, methanol, isopropanol, butanol, triethylamine, nitromethane, octane, pentane, tetrahydrofuran (THF), toluene, 1,1,1-trichloroethane, 1,1,2-trichloroethylene, water, xylene, and combinations thereof. In general, the paclitaxel is dissolved in the volatile solvent to form a paclitaxel solution having a concentration of between 0.01 and 80% weight to volume (w/v), more preferably between 0.025 and 30% (w/v).
Aqueous solvents or mixtures of aqueous and organic solvents, such as water-alcohol mixtures, can be used to dissolve the drug. In a preferred embodiment the volatile solvent is an aqueous mixture of an alcohol such as methanol or ethanol where the alcohol percent is in the range 40-100% (v/v).
III. Pore Forming Agents
Pore forming agents are volatile materials that preferably are used during the process to create porosity in the resultant matrix. The pore forming agent can be a volatilizable solid or volatilizable liquid.
1. Liquid Pore Forming Agent
The liquid pore forming agent must be immiscible with the paclitaxel solvent and volatilizable under processing conditions compatible with the paclitaxel. To effect pore formation, the pore forming agent first is emulsified with the paclitaxel solvent. Then, the emulsion is further processed to remove the paclitaxel solvent and the pore forming agent simultaneously or sequentially using evaporation, vacuum drying, spray drying, fluid bed drying, lyophilization, or a combination of these techniques.
The selection of liquid pore forming agents will depend on the paclitaxel solvent. Representative liquid pore forming agents include water; dichloromethane; alcohols such as ethanol, methanol, or isopropanol; acetone; ethyl acetate; ethyl formate; dimethylsulfoxide; acetonitrile; toluene; xylene; dimethylforamide; ethers such as THF, diethyl ether, or dioxane; triethylamine; foramide; acetic acid; methyl ethyl ketone; pyridine; hexane; pentane; furan; water; and cyclohexane.
The liquid pore forming agent typically is used in an amount that is between 1 and 50% (v/v), preferably between 5 and 25% (v/v), of the paclitaxel solvent emulsion.
2. Solid Pore Forming Agent
The solid pore forming agent must be volatilizable under processing conditions which do not harm the paclitaxel compositions. The solid pore forming agent can be (i) dissolved in the paclitaxel solution, (ii) dissolved in a solvent which is not miscible with the paclitaxel solvent to form a solution which is then emulsified with the paclitaxel solution, or (iii) added as solid particulates to the paclitaxel solution. The solution, emulsion, or suspension of the pore forming agent in the paclitaxel solution then is further processed to remove the paclitaxel solvent, the pore forming agent, and, if appropriate, the solvent for the pore forming agent simultaneously or sequentially using evaporation, spray drying, fluid bed drying, lyophilization, vacuum drying, or a combination of these techniques.
In a preferred embodiment, the solid pore forming agent is a volatile salt, such as salts of volatile bases combined with volatile acids. Volatile salts are materials that can transform from a solid or liquid to a gaseous state using added heat and/or vacuum. Examples of volatile bases include ammonia, methylamine, ethylamine, dimethylamine, diethylamine, methylethylamine, trimethylamine, triethylamine, and pyridine. Examples of volatile acids include carbonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, formic acid, acetic acid, propionic acid, butyric acid, and benzoic acid. Preferred volatile salts include ammonium bicarbonate, ammonium acetate, ammonium chloride, ammonium benzoate and mixtures thereof.
Other examples of solid pore forming agents include iodine, phenol, benzoic acid (as acid not as salt), and naphthalene.
The solid pore forming agent is used in an amount between 0.5 and 1000% (w/w), preferably between 1 and 600% (w/w), and more preferably between 1 and 100% (w/w), of the paclitaxel.
IV. Method of Making the Porous Paclitaxel Matrix
The paclitaxel matrices preferably are made by (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution. In a preferred embodiment, spray drying, optionally followed by lyophilization or vacuum drying, is used to remove the solvents and the pore forming agent. The removal of the pore forming agent can be conducted simultaneously with or following removal of enough solvent to solidify the droplets. Production can be carried out using continuous, batch, or semi-continuous processes.
First, paclitaxel is dissolved in an appropriate solvent. The concentration of the paclitaxel in the resulting paclitaxel solution typically is between about 0.01 and 80% (w/v), preferably between about 0.025 and 30% (w/v).
Next, the paclitaxel solution is combined, typically under mixing conditions, with the pore forming agent or solution thereof. If a liquid pore forming agent is used, it is first emulsified with the paclitaxel solution to form droplets of pore forming agent dispersed throughout the paclitaxel solution. If a solid pore forming agent is used, it is dissolved either directly in the paclitaxel solution to form a solution of paclitaxel/pore forming agent, or it is first dissolved in a second solvent. If the second solvent is immiscible with the paclitaxel solvent, the solution of the pore forming agent is emulsified with the paclitaxel solution to form droplets of the pore forming agent solution dispersed throughout the paclitaxel solution. If the second solvent is miscible with the paclitaxel solution, the two solutions are mixed to form a single solution. A solid pore forming agent alternatively can be added directly to the paclitaxel solution as solid particulates, preferably between about 10 nm and 10 μm in size, to form a suspension of pore forming agent in the paclitaxel solution. Subsequently, the solid pore forming agent particle size can be reduced by further processing the resulting suspension, for example, using homogenization or sonication techniques known in the art.
Then, the solution, emulsion, or suspension is further processed to remove the paclitaxel solvent and the pore forming agent simultaneously or sequentially, using evaporation, spray drying, fluid bed drying, lyophilization, vacuum drying, or a combination of these techniques. In a preferred embodiment, the solution, emulsion, or suspension is spray-dried. As used herein, “spray dry” means to atomize the solution, emulsion, or suspension to form a fine mist of droplets (of paclitaxel solution having solid or liquid pore forming agent dispersed throughout), which immediately enter a drying chamber (e.g., a vessel, tank, tubing, or coil) where they contact a drying gas. The solvent and pore forming agents evaporate from the droplets into the drying gas to solidify the droplets, simultaneously forming pores throughout the solid. The solid (typically in a powder, particulate form) then is separated from the drying gas and collected.
The temperature of the inlet and outlet ports of the drying chamber, as well as the flow rates of the feed solution, atomization gas, and drying gas, can be controlled to produce the desired products. In a particularly preferred embodiment, the spray drying methods described in U.S. Pat. No. 5,853,698 to Straub et al., which is hereby incorporated by reference, are adapted to make the paclitaxel matrices described herein.
The paclitaxel present in the solids or powder produced may be in a crystalline or an amorphous state, or may be mixture of such states. The state generally depends on how the droplets are dried and the excipients present.
In embodiments in which at least one pore forming agent is combined with the paclitaxel solution to form an emulsion, a surfactant or emulsifying agent can be added to enhance the stability of the emulsion. A variety of surfactants may be incorporated in this process, preferably to an amount between 0.1 and 5% by weight. Exemplary emulsifiers or surfactants which may be used include most physiologically acceptable emulsifiers, for instance egg lecithin or soya bean lecithin, or synthetic lecithins such as saturated synthetic lecithins, for example, dimyristoyl phosphatidyl choline, dipalmitoyl phosphatidyl choline or distearoyl phosphatidyl choline or unsaturated synthetic lecithins, such as dioleyl phosphatidyl choline or dilinoleyl phosphatidyl choline. Other hydrophobic or amphipathic compounds can be used in place of the phospholipid, for example, cholesterol. Emulsifiers also include surfactants such as free fatty acids, esters of fatty acids with polyoxyalkylene compounds like polyoxypropylene glycol and polyoxyethylene glycol; ethers of fatty alcohols with polyoxyalkylene glycols; esters of fatty acids with polyoxyalkylated sorbitan; soaps; glycerol-polyalkylene stearate; glycerol-polyoxyethylene ricinoleate; homo- and co-polymers of polyalkylene glycols; polyethoxylated soya-oil and castor oil as well as hydrogenated derivatives; ethers and esters of sucrose or other carbohydrates with fatty acids, fatty alcohols, these being optionally polyoxyalkylated; mono-, di- and tri-glycerides of saturated or unsaturated fatty acids, glycerides of soya-oil and sucrose.
Other emulsifiers include natural and synthetic forms of bile salts or bile acids, both conjugated with amino acids and unconjugated such as taurodeoxycholate and cholic acid.
V. Paclitaxel Matrix Applications
The paclitaxel matrices described herein are useful in formulations for administration to a patient in need of the paclitaxel. As used herein, “patient” refers to animals, including mammals, preferably humans. The porous matrices or formulations thereof are suitable for administration of the paclitaxel by a variety of routes, for example, parenteral, mucosal, oral, topical/transdermal administration, for local, regional, or systemic effect. Examples of parenteral routes include intravenous, intrarterial, intracardiac, intrathecal, intraosseous, intraarticular, intrasynovial, intracutaneous, subcutaneous, and intramuscular. Examples of mucosal routes include pulmonary (intrarespiratory), buccal, sublingual, intranasal, rectal, and vaginal administration. The porous matrices can be formulated for intraocular, conjunctival, aural, urethral, intracranial, intralesional, and intratumoral administration.
In a preferred embodiment, the paclitaxel matrix is in the form of powder, which can be reconstituted with an aqueous medium, such as physiological saline, and administered parenterally, such as intramuscularly, subcutaneously, or intravenously. An advantage of the formulations described herein is that they can be used to convert paclitaxel which must be infused (e.g., to avoid precipitation of the paclitaxel following bolus injection) to a bolus formulation, avoiding unacceptable precipitation of paclitaxel in vivo or for local delivery.
Alternatively, the matrix can be further processed using standard techniques into tablets or capsules for oral administration. These techniques are described, for example, in Ansel, et al., “Pharmaceutical Dosage Forms and Paclitaxel Delivery Systems,” 6th Ed., (Williams & Wilkins 1995), which is incorporated herein by reference.
The present invention will be further understood with reference to the following non-limiting examples.
Examples 1-2 demonstrate production of paclitaxel matrices using different wetting agents and different solvents.
Examples 3-4 describe the analyses which were used to characterize the porous paclitaxel matrices produced in Examples 1-2. These characteristics include density and dissolution properties.
Example 6 describes the antitumor activity of the paclitaxel formulation produced in example 5 in female athymic NCr-nu mice in which the MDA-MB 435 breast tumor has been implanted subcutaneously (sc).
The following materials and equipment were used in the examples. PEG 3350, polyvinylpyrrolidone K-15, TWEEN™ 80, and ammonium bicarbonate, were obtained from Spectrum Chemicals (Gardena, Calif.). Paclitaxel was obtained from Hauser (Boulder, Colo.). Methylene chloride was obtained from EM Science (Gibbstown, N.J.). All emulsions were produced using a Virtis IQ2 homogenizer (Virtis, Gardiner, N.Y.). Formulations were spray dried on a benchtop spray dryer using an air atomizing nozzle.
A paclitaxel-loaded organic solution was prepared by dissolving 1.0 g of paclitaxel, 0.10 g of TWEEN™ 80, and 0.10 g of polyvinylpyrrolidone K-15 in 160 ml of ethanol. An aqueous solution composed of 0.42 g of ammonium bicarbonate and 1.0 g of mannitol in 40 ml of DI water was added to the ethanol solution and mixed. The resulting 80% ethanol solution was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas. Spray drying conditions were as follows: 20 ml/min solution flow rate, 60 L/min atomization gas rate, 100 kg/hr drying gas rate, and 55° C. outlet.
A paclitaxel-loaded organic solution was prepared by dissolving 0.4 g of paclitaxel, 0.10 g of TWEEN™ 80, and 0.04 g of polyvinylpyrrolidone K-15 in 160 ml of ethanol. An aqueous solution composed of 0.30 g of ammonium bicarbonate and 1.0 g of mannitol in 40 ml of DI water was added to the ethanol solution and mixed. The resulting 80% ethanol solution was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas. Spray drying conditions were as follows: 20 ml/min solution flow rate, 60 L/min atomization gas rate, 100 kg/hr drying gas rate, and 55° C. outlet temperature.
The in vitro dissolution rates of the powders produced in Examples 1-2 were compared to the dissolution rates of the non-formulated paclitaxel.
Studies were conducted in PBS containing 0.08% TWEEN™ 80 (T80/PBS). T80/PBS (10 mL) was added to an appropriate amount of material being tested to contain 5 mg of paclitaxel in a 15 mL polypropylene conical tube, and the suspension was vortexed for 3-4 minutes. The suspension (0.25 mL) was then added to 250 mL of T80/PBS in a 600 mL glass beaker for dissolution analysis. All dissolution studies were conducted using overhead mixing. The mixer used was an IKARW16 Basic Mixer with a R1342 impeller shaft running at stirring rate 5. Samples were removed via pipette, filtered through 0.22 micron CA syringe filter, and then analyzed. Dissolution curves are presented as percent of complete dissolution.
HPLC analysis was performed directly on the filtered aqueous solutions using High Pressure Liquid Chromatography (“HPLC”) (Hewlett Packard Series 1100 HPLC). The chromatographic conditions included a Nucleosil column (5:m, C18, 100A, 250×4.6 mm), a mobile phase of 2 mM H3PO4/Acetonitrile (2:3) at a flow rate of 1.5 mL/min, UV detection at 227 nm, and a run time of 25 min.
The in vitro dissolution rates of the porous paclitaxel matrices produced in examples 1-2 are provided in FIG. 1. The in vitro dissolution of the porous paclitaxel matrices are compared to the bulk paclitaxel of interest. In all cases, the time for 80% dissolution of the porous paclitaxel matrices is greater than 1000 times shorter than the time for 80% of the bulk paclitaxel to dissolve. The rate of dissolution which is approximated as the slope of the curve is greater than 1000 times greater for the porous paclitaxel matrices of Examples 1-2 as compared to the specific bulk paclitaxel of interest.
The densities of the dry powder produced in Examples 1-2 are summarized in Table 1. Density was measured using Transaxial Pressure (“TAP”) with a Micromeritics GeoPyc 1360 using a consolidation force of 8 Newtons. The density of the porous matrices is less than 1.0 g/mL for Examples 1-2.
Particle Density Analysis
A paclitaxel-loaded organic solution was prepared by dissolving 2.0 g of paclitaxel, 0.20 g of polyvinylpyrrolidone, and 0.20 g of TWEEN™ 80 in 320 ml of ethanol. An aqueous solution composed of 0.85 g of ammonium bicarbonate and 2.0 g of mannitol in 80 ml of DI water was added to the organic solution (phase ratio 1:4). Prior to spray drying, the solution was filtered through a 0.22 μm PVDF membrane. A benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas were used. Spray drying conditions were as follows; 20 ml/min solution flow rate, 60 L/min atomization gas rate, 100 kg/hr drying gas rate, and 54° C. outlet temperature.
The antitumor activity of the paclitaxel formulation produced in Example 5 was tested in female athymic NCr-nu mice in which the MDA-MB 435 breast tumor has been implanted subcutaneously (sc), using doses of 7.5, 15, 30, and 45 mg/kg. Mice were implanted subcutaneously with 30-40 mg fragments of the MDA-MB 435 tumor on Day 0. Treatment with the porous paclitaxel matrix began when the tumors ranged in size from 75-150 mg. Two control groups were included, a vehicle-treated control group and a TAXOL™ treated group. The dose of the TAXOL™ treated group was set at the maximum tolerated dose in this animal model. Treatment was administered once a day intravenously for five days. Mice were observed daily for survival. Tumor measurements were recorded twice weekly. Tumors were measured in two dimensions using calipers and converted to tumor mass using the volume of a prolate ellipsoid and assuming unit density. Median tumor mass for the various groups in shown in
Modifications and various of the present invention will be obvious to those of skill in the art from the foregoing detailed description. Such modifications and various are intended to come within the scope of the following claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4818542||Mar 31, 1986||Apr 4, 1989||The University Of Kentucky Research Foundation||Porous microspheres for drug delivery and methods for making same|
|US4898734||Feb 29, 1988||Feb 6, 1990||Massachusetts Institute Of Technology||Polymer composite for controlled release or membrane formation|
|US5382437||Oct 25, 1993||Jan 17, 1995||Hunter Research Corporation||Frozen liquified gas composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs|
|US5468598||Apr 18, 1994||Nov 21, 1995||Eastman Kodak Company||Solid particle dispersions for imaging systems|
|US5470583||May 10, 1994||Nov 28, 1995||Eastman Kodak Company||Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation|
|US5500331||May 25, 1994||Mar 19, 1996||Eastman Kodak Company||Comminution with small particle milling media|
|US5510118||Feb 14, 1995||Apr 23, 1996||Nanosystems Llc||Process for preparing therapeutic compositions containing nanoparticles|
|US5513803||May 25, 1994||May 7, 1996||Eastman Kodak Company||Continuous media recirculation milling process|
|US5518187||Jan 12, 1994||May 21, 1996||Nano Systems L.L.C.||Method of grinding pharmaceutical substances|
|US5518738||Feb 9, 1995||May 21, 1996||Nanosystem L.L.C.||Nanoparticulate nsaid compositions|
|US5534270||Feb 9, 1995||Jul 9, 1996||Nanosystems Llc||Method of preparing stable drug nanoparticles|
|US5552160||Mar 13, 1995||Sep 3, 1996||Nanosystems L.L.C.||Surface modified NSAID nanoparticles|
|US5560932||Jan 10, 1995||Oct 1, 1996||Nano Systems L.L.C.||Microprecipitation of nanoparticulate pharmaceutical agents|
|US5565188||Feb 24, 1995||Oct 15, 1996||Nanosystems L.L.C.||Polyalkylene block copolymers as surface modifiers for nanoparticles|
|US5569448||Jan 24, 1995||Oct 29, 1996||Nano Systems L.L.C.||Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions|
|US5571536||Feb 6, 1995||Nov 5, 1996||Nano Systems L.L.C.||Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids|
|US5580579||Feb 15, 1995||Dec 3, 1996||Nano Systems L.L.C.||Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers|
|US5587143||Jun 28, 1994||Dec 24, 1996||Nanosystems L.L.C.||Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions|
|US5591456||Feb 10, 1995||Jan 7, 1997||Nanosystems L.L.C.||Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer|
|US5609998||Apr 6, 1995||Mar 11, 1997||Eastman Kodak Company||Process for dispersing concentrated aqueous slurries|
|US5622279||Sep 13, 1995||Apr 22, 1997||Schutz; Udo||Pallet container for transportation and storage of liquids|
|US5622938||May 19, 1995||Apr 22, 1997||Nano Systems L.L.C.||Sugar base surfactant for nanocrystals|
|US5657931||May 19, 1995||Aug 19, 1997||Eastman Kodak Company||Stable aqueous solid particle dispersions|
|US5662279||Dec 5, 1995||Sep 2, 1997||Eastman Kodak Company||Process for milling and media separation|
|US5662883||Jan 10, 1995||Sep 2, 1997||Nanosystems L.L.C.||Microprecipitation of micro-nanoparticulate pharmaceutical agents|
|US5665331||Jan 10, 1995||Sep 9, 1997||Nanosystems L.L.C.||Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers|
|US5716642||Jan 10, 1995||Feb 10, 1998||Nano Systems L.L.C.||Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents|
|US5718919||Feb 24, 1995||Feb 17, 1998||Nanosystems L.L.C.||Nanoparticles containing the R(-)enantiomer of ibuprofen|
|US5747001||Feb 24, 1995||May 5, 1998||Nanosystems, L.L.C.||Aerosols containing beclomethazone nanoparticle dispersions|
|US5762961||Feb 9, 1996||Jun 9, 1998||Quadrant Holdings Cambridge Ltd.||Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof|
|US5853698||Nov 8, 1996||Dec 29, 1998||Acusphere, Inc.||Method for making porous microparticles by spray drying|
|US5855913||Jan 16, 1997||Jan 5, 1999||Massachusetts Instite Of Technology||Particles incorporating surfactants for pulmonary drug delivery|
|US5916596||Oct 1, 1996||Jun 29, 1999||Vivorx Pharmaceuticals, Inc.||Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof|
|US5919434||Sep 5, 1994||Jul 6, 1999||Nycomed Imaging As||Polymeric surfactant-encapsulated microbubbles and their use in ultrasound imaging|
|US5942253||Oct 12, 1995||Aug 24, 1999||Immunex Corporation||Prolonged release of GM-CSF|
|US5976574||Dec 29, 1997||Nov 2, 1999||Inhale Therapeutic Systems||Processes for spray drying hydrophobic drugs in organic solvent suspensions|
|US5985285||Mar 13, 1996||Nov 16, 1999||The Secretary Of State For Defence In Her Britanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland||Vaccines for plague|
|US6001336||Dec 29, 1997||Dec 14, 1999||Inhale Therapeutic Systems||Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof|
|US6096331||Sep 9, 1997||Aug 1, 2000||Vivorx Pharmaceuticals, Inc.||Methods and compositions useful for administration of chemotherapeutic agents|
|US6395300||Nov 4, 1999||May 28, 2002||Acusphere, Inc.||Porous drug matrices and methods of manufacture thereof|
|US6423345||Feb 22, 1999||Jul 23, 2002||Acusphere, Inc.||Matrices formed of polymer and hydrophobic compounds for use in drug delivery|
|US6565885||Dec 22, 1998||May 20, 2003||Inhale Therapeutic Systems, Inc.||Methods of spray drying pharmaceutical compositions|
|US6645528||Oct 23, 2000||Nov 11, 2003||Acusphere, Inc.||Porous drug matrices and methods of manufacture thereof|
|US6962696 *||Aug 24, 2000||Nov 8, 2005||Vion Pharmaceuticals Inc.||Compositions and methods for tumor-targeted delivery of effector molecules|
|US20010018072||Apr 9, 2001||Aug 30, 2001||Imarx Therapeutics, Inc.||Solid matrix therapeutic compositions|
|US20020009493||Dec 15, 2000||Jan 24, 2002||Schwendeman Steven P.||Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers|
|US20020142050 *||Jan 22, 2002||Oct 3, 2002||Acusphere Inc.||Porous drug matrices and methods of manufacture thereof|
|US20030035845||Mar 7, 2002||Feb 20, 2003||Zale Stephen E.||Composition for sustained release of non-aggregated erythropoietin|
|US20050048116 *||Aug 24, 2004||Mar 3, 2005||Julie Straub||Porous drug matrices and methods of manufacture thereof|
|CA2136704A1||Nov 25, 1994||May 28, 1995||Gunter Ditzinger||Medicinal aerosol formulation|
|DE3713326A1||Apr 21, 1987||Oct 29, 1987||Basf Ag||Spray-dried active substance granules and their preparation|
|EP0655237A1||Nov 21, 1994||May 31, 1995||Hoechst Aktiengesellschaft||Medicinal aerosol formulation|
|GB1265615A||Title not available|
|WO1991018590A1||Jun 5, 1991||Dec 12, 1991||Kabi Pharmacia Ab||Process for the manufacture of porous cellulose matrices|
|WO1998031346A1||Nov 17, 1997||Jul 23, 1998||Massachusetts Institute Of Technology||Preparation of particles for inhalation|
|WO1998051282A1||May 12, 1998||Nov 19, 1998||Imarx Pharmaceutical Corp.||Solid porous matrices and methods of making and using the same|
|WO1999056731A1||Mar 8, 1999||Nov 11, 1999||Acusphere, Inc.||Matrices formed of polymer and hydrophobic compounds for use in drug delivery|
|WO2000061147A1||Apr 8, 2000||Oct 19, 2000||Southern Research Institute||Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol|
|1||Adeyeye & Price, "Chemical dissolution stability and microscopic evaluation of suspensions of ibuprofen and sustained release ibuprofen-wax microspheres," J. Microencapsul. 14(3):357-77 (1997).|
|2||Ahn, et al., "Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form," Drug Dev. Ind. Pharm. 24(7):697-701 (1998).|
|3||Akade, et al., "Influence of polyethylene glycol 6000 and mannitol on the in-vitro dissolution properties of nitrofurantoin by the dispersion technique," Pharmazie. 41(12):849-51 (1986).|
|4||Akbarieh & Tawashi, "Morphic features of solid particles after micronization in the fluid energy mill," Int. J. Pharm. 35:81-89 (1987).|
|5||Allen, et al., "Dissolution rates of corticosteroids utilizing sugar glass dispersions," J. Pharm. Sci. 66(4):494-97 (1977).|
|6||Appel & Zentner, "Use of modified ethylcellulose lattices for microporous coating of osmotic tablets," Pharm. Res. 8(5):600-04(1991).|
|7||Arias, "Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols," Pharm. Acta. Helv. 71(4):229-35 (1996).|
|8||Arias, et al., "The application of solid dispersion technique with D-mannitol to the improvement in oral absorption of triamterene," J. Drug Target 2(1):45-51 (1994).|
|9||Arteaga, et al., "Dissolution velocity of different calcium preparations used in the clinical field," Rev. Med. Chil. 124(11):1325-33 (1996).|
|10||Badiger, et al., "Porogens in the preparation of microporous hydrogels based on poly(ethylene oxides)," Biomaterials 14:1059-63 (1993).|
|11||Bodmeier & Paeratakul, "Spherical agglomerates of water-insoluble drugs," J. Pharm. Sci. 78(11)964-67 (1989).|
|12||Borgstrom, et al., "In vitro and in vivo evaluation of controlled-release and enteric-coated formulations of sodium salicylate," Biopharm. Drug Dispos. 5(3):261-72 (1984).|
|13||Buckton, et al., "The effect of comminution technique on the surface energy of a powder," Int. J. Pharm. 47:121-28 (1998).|
|14||Cardorniga, et al., "In vitro evaluation of the dissolution rate of crystalline suspensions destined to intramuscular administration," Eur. J. Drug Metab. Pharmacokinet. Spec No. 3:379-84 (1991).|
|15||Chaumeil, "Micronization: a method of improving the bioavailability of poorly soluble drugs," Meth. Find. Exp. Clin. Pharmacol. 20(3):211-15 (1998).|
|16||Chen & Hao, "Factors affecting zero-order release kinetics of porous gelatin capsules," Drugs Dev. Ind. Pharm. 24(6):557-62 (1998).|
|17||Chen & Hao, "In vitro performance of floating sustained-release capsule of verapamil," Drug Dev. Ind. Pharm. 24(11):1067-72 (1998).|
|18||Chiou & Riegelman, "Oral absorption of griseofulvin in dogs: increased absorption via solid dispersion in polyethylene glycol 6000," J. Pharm. Sci. 59(7):937-42 (1970).|
|19||Chiou & Riegelman, "Pharmaceutical applications of solid dispersion systems," J. Pharm. Sci. 60:1281-302 (1971).|
|20||Chiou et al., "Enhancement of dissolution rates of poorly water-soluble drugs by crystallization in aqueous surfactant solutions I:Sulfathiazole, Prednisone, and Chloramphenicol," J. Pharm. Sci. 65:1702-04 (1976).|
|21||Christensen et al., "Storage of polyvinylpyrrolidone (PVP) in tissues following long-term treatment with a PVP-containing vasopressin preparation," Act. Med. Scand. 204:295-98 (1978).|
|22||Corrigan & Holohan, "Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties," J. Pharm. Pharmacol. 36(4):217-21 (1984).|
|23||Davis et al, "Polymeric microspheres as drug carriers," Biomaterials 9:111-115 (1988).|
|24||De Almeida, et al., "Modeling dissolution of sparingly soluble multisized powders," J. Pharm. Sci. 86:726-32 (1997).|
|25||Dordunoo, et al., "Physical stability of solid dispersions containing triamterene or temazepam in polyethylene glycols," J. Pharm. Pharmacol. 49(4):390-96 (1997).|
|26||Dressman & Fleisher, "Mixing-tank model for predicting dissolution rate control or oral absorption," J. Pharm. Sci. 75(2):109-16 (1986).|
|27||Eichman & Robinson, "Mechanistic studies on effervescent-induced permeability enhancement," Pharm. Res. 15(6):925-30 (1998).|
|28||El-Fattah, et al., "Enhancement of dissolution rate of hydrochlorothiazide via solid dispersion," Pharmazie. 41(11):790-93 (1986).|
|29||Feinstein & Sciarra, "Development and evaluation of a dexamethasone timed-release aerosol formulation," J. Pharm. Sci. 64:408-13 (1975).|
|30||Fenimore & Loy, "Injectible dispersion of .sup.9-tetrahydrocannabinol in saline using polyvinyl pyrrolidone," J. Pharm. Pharmac. 23:310 (1971).|
|31||Ford, "The current status of solid dispersions," Pharm. Act. 61:69-88 (1986).|
|32||Freitass & Muller, "Spray-drying of solid lipid nanoparticles (SLN.TM.)," Eur. J. Pharm. Biopharm. 46(2):145-51 (1998).|
|33||Galia, et al., "Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs," Pharm. Res. 15(5):698-705 (1998).|
|34||Genta, et al., "Improvement of dexamethasone dissolution rate from spray-dried chitosan microspheres," S.T.P. Pharm. Sciences 5(3):202-07 (1995).|
|35||Hastedt & Wright, "Diffusion in porous materials above the percolation threshold," Pharm. Res. 7(9):893-901 (1990).|
|36||Hirschberg, et al., "Oral absorption of CGS-20625, an insoluble drug, in dogs and man," J. Pharmacokinet. Biopharm. 23(1):11-23 (1995).|
|37||Hong, et al., "Accelerated oral absorption of glicazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide," J. Controlled Release 51(2-3):185-92 (1998).|
|38||Imai, et al., "Enhancement of the dissolution rates of poorly water-soluble drugs by water-soluble gelatin," Chem. Pharm. Bull. (Tokyo). 37(8):2251-52 (1989).|
|39||Imai, et al., "Rapidly absorbed solid oral formulations of ibuprofen using water-soluble gelatin," J. Pharm. Pharmacol. 42(9):615-19 (1990).|
|40||Ju, et al., "Drug release from hydropohilic matrices. 1. New scaling laws for predicting polymer and drug release based on the polymer disentanglement concentration and the diffusion layer," J. Pharm. Sci. 84(12):1455-63 (1995).|
|41||Kagkadis, et al., "A freeze-dried injectable form of ibupropen: development and optimisation using response surface methodology," PDA J. Pharm. Sci. Technol. 50(5):317-23 (1996).|
|42||Kai, et al., "Oral absorption improvement of poorly soluble drug using solid dispersion technique," Chem. Pharm. Bull. 44(3):568-71 (1996).|
|43||Kaneniwa & Watari, "Dissolution of slightly soluble drugs. I. Influence of particle size on dissolution behavior," Chem. Pharm. Bull. 22:1699-705 (1974).|
|44||Kaur, et al., "Comparison of polyethylene glycol and polyoxyethylene stearate as excipients for solid dispersion systems of griseofulvin and tolbutamide II: dissolution and solubility studies," J. Pharm. Sci. 69(11):1312-26 (1980).|
|45||Kawashima, et al., "Improvement of solubility and dissolution rate of poorly water-soluble salicylic acid by a spray-drying technique," J. Pharm. Pharmacol. 27(1):1-5 (1975).|
|46||Khan & Jiabi, "Preparation, characterization, and dissolution studies of ibuprofen solid dispersions using polyethylene glycol (PEG), talc, and PEG-talc as dispersion carriers," Drug Dev. Ind. Pharm. 24(5):455-62 (1998).|
|47||Khan, et al., "Controlled release coprecipitates:formulation considerations," J. Control. Rel. 37:131-41 (1995).|
|48||Kim & Yoon, "Development of digoxin dry elixir as a novel dosage form using a spray-drying technique," J. Microencapsul. 12(5):547-56 (1995).|
|49||Kincl, et al., "Increasing oral bioavailability of progesterone by formulation," J. Steroid Biochem. 9(1):83-84 (1978).|
|50||Kondo, et al., "Pharmacokinetics of micronized, poorly water-soluble drug, HO-221, in experimental animals," Biol. Pharm. Bull. 16(8):796-800 (1993).|
|51||Kubo & Mizobe, "Improvement of dissolution rate and oral bioavailability of sparingly water-soluble drug (+/-)-5-[[2(-2-naphthalenylmethyl)-5-benzoxazolyl]-2, 4-thiazolidinedione, in co-ground mixture with D-mannitol," Biol. Pharm. Bull. 20(4):460-63 (1997).|
|52||Kubo, et al., "Enhancement of oral bioavilability and pharmacological effect of 1-(3,4-dimethoxyphenl)-2,3-bis(methoxycarbonyl)-4hydroxy-6,7,8-trimethoxynaphthalene (TA-7552), a new hypocholesterolemic agent, by micronization in co-ground mixture with D-mannitol," Biol. Pharm. Bull. 19(5):741-47 (1996).|
|53||Lee, et al., "Mathematical modelling of the release of drug from porous, nonswelling transdermal drug-delivery devices, " IMA J. Math. Appl. Med. Biol. 15(2):135-63 (1998).|
|54||Lemos-Senna, et al., "Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphillic cyclodextrin nanospheres," Pharm. Dev. Tech. 3:85-94 (1998).|
|55||Leucuta, et al., "The kinetics of nifefipine release from porous hydrophillic matrices and the pharmacokinetics in man," Pharmazie 43:845-48 (1988).|
|56||Lin et al., "Improved oral absorption of L-365260, a poorly soluble drug," Biopharm. Drug Dispos.. 17(1):1-15 (1996).|
|57||Lin, et al., "Preparation of enteric-coated microspheres of Mycoplasma hyopneumoniae vaccine with cellulose acetate phthalate: (II). Effect of temperature and pH on the stability and release behaviour of microspheres," J. Microencapsul. 8(4):537-45 (1991).|
|58||Martindale, The Extra Pharmacopoeia, 711 Dissolution, pp. 1791-1792, 30th Ed. (The Pharmaceutical Press, London 1993).|
|59||Mason & Winer, "Kinetics of aspirin salicylic acid, and salicyluric acid following oral administration of asprin as a tablet and two buffered solutions," J. Pharm. Sci. 70(3):262-65 (1981).|
|60||Migliaresi, et al., "Physical characterization of microporous poly(2-hydroxyethyl methacrylate) gels, " J. Biomed. Mater. Res. 15:307-17 (1981).|
|61||Mishra & Yalkowsky, "A flat circular hole device for zero-order release of drugs: characterization of the moving dissolution boundary, " Pharm. Res. 7(11):1195-97 (1990).|
|62||Morris, et al., "Structural properties of polyethylene glycol-polsorbate 80 mixture, a solid dispersion vehicle," J. Pharm. Sci. 81(12):1185-88 (1992).|
|63||Mu, et al, "Fabrication, characterization and in vitro release of paclitaxel formulation (Taxol(R)) loaded poly (lacto-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers," J. Control. Rel. 76:239-254 (2001).|
|64||Najib, et al., "The adsorption of hydrophilic polymers at the liquid-solid interface," J. Pharm. Pharmac. 29:43P (1977).|
|65||Nishimura, et al., "Dosage form design for improvement of bioavailability of levodopa VI: formulation of efferevescent enteric-coated tablets," J. Pharm. Sci. 73(7):942-46 (1984).|
|66||Nystrom & Westerberg, "The use of ordered mixtures for improving the dissolution rate of low solubility compounds," J. Pharm. Pharmacol. 38(3):161-65 (1986).|
|67||Nystrom, et al., "Dissolution rate measurements of sparingly soluble compounds with the Coulter Counter model TAII" J. Pharm. Pharmacol. 37(4):217-21 (1985).|
|68||Oku et al, "Long-circulating liposomes," Crit. Rev. Ther. Drug Carrier Syst". 19:231-270 (1994).|
|69||Otsuka, et al. "Hygroscopic stability and dissolution properties of spray-dried solid dispersions of furosemide with Eudragit, "J. Pharm. Sci. 82(1):32-38 (1993).|
|70||Pace, et al., "Novel injectable formulations of insoluble drugs," Pharmaceutical Technology 116-34 (1999).|
|71||Perkins, et al, "Novel therapeutic non-particles (liposomes):trapping poorly water soluble compounds", Int. J. Pharm. 200:27-39 (2001).|
|72||Pillay & Fassihi, "A new method for dissolution studies of lipid-filled capsules employing nifedipine as a model drug," Pharm. Res. 16(2):333-37 (Mar. 1999).|
|73||Reddy, et al., "Dissolution characteristics and oral absorption of digitoxin and digoxin coprecipitates," J. Pharm. Sci. 65(12):1753-58 (1976).|
|74||Ridolfo, et al., "Benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans," J. Pharm. Sci. 68(7):850-52 (1979).|
|75||Roland & Paeratakul, "Spherical Agglomerates of Water-Insoluble Drugs, " J. Pharma. Sci. 78(11):964-67 (1989).|
|76||Saano, et al., "Relative pharmacokinetics of three oral 400 mg ibuprofen dosage forms in healthy volunteers," Int. J. Clin. Pharm. Ther. Toxic. 29:381-85 (1991).|
|77||Sakaeda and Hirano, "Effect of composition on biological fate of oil particles after intravenous injectionof o/w lipid emulsions", J. Drug. Target, 6:273-284 (1998).|
|78||Schroder & Sabel, "Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central: analgesic effects of i.v. dalargin injections," Brain Research 710:121-24 (1996).|
|79||Serajuddin, et al., "Effects of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions," J. Pharm. Sci. 77(5):414-17 (1988).|
|80||Serajuddin, et al., "Improved dissolution of a poorly water-soluble drug from solid dispersions in polyethylene glycol: polysorbate 80 mixtures," J. Pharm. Sci. 79(5):463-64 (1990).|
|81||Serajuddin, et al., "Water-migration from soft gelatin capsule shell to fill material and its effect on drug solubility," J. Pharm. Sci. 75(1):62-64 (1986).|
|82||Suzuki & Sunada, "Comparison of nicotinamide, ethylurea, and polyethylene glycol as carriers for nifedipine solid dispersion systems," Chem. Pharm. Bull. 45:1688-93 (1997).|
|83||Suzuki & Sunada, "Infuence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers," Chem. Pharm. Bull. 46:482-87 (1998).|
|84||Sweetana & Akers, "Solubility principles and practices for parenteral drug dosage form development," PDA J. Pharm. Sci. Technol. 50(5):330-42 (1996).|
|85||Takenaka, et al., "Preparations of solid particulates of theophylline-ethylenediamine complex by a spray-drying technique," J. Pharm. Sci. 71(8):914-19 (1982).|
|86||Takeuchi, et al., "Enhancement of the dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent deposition method and disintegrants," J. Pharm. Pharmacol. 39(10):769-73 (1987).|
|87||Tasic, et al., "The influence of beta-cyclodextrin on the solubility and dissolution rate of paracetamol solid dispersions," J. Pharm. Pharmacol. 44(1):52-55 (1992).|
|88||Tingstad, et al., "Dissolution rate studies. III. Effect of type and intensity of agitation on dissolution rate," J. Pharm. Sci. 62(2):293-97 (1973).|
|89||Torrado, et al., "Egg albumin microspheres containing paracetamol for oral administration. I. In vitro characterization," J. Microencapsul. 74(4):463-70 (1990).|
|90||Traue, et al., "Spray products of sparingly soluble drugs. 1. In vitro study of spray products of nitrazepam in a starch hydrolysis product" Pharmazie 43(5): 368-369 (1988).|
|91||Velaz, et al., "Effect of PEG 4000 on the dissolution rate of naproxen," Eur. J. Drug Metab. Pharmacokinet. 23(2):103-08 (1998).|
|92||Venkataram & Rogers, "Characteristics of drug-phospholipid coprecipitates I: Physical properties and dissolution behavior of griseofulvin-dimyristoylphosphatidylcholine systems," J. Pharm. Sci. 73(6):757-61 (1984).|
|93||Vudathala & Rogers, "Dissolution of fludrocortisone from phospholipid coprecipitates," J. Pharm. Sci. 81(3):282-86 (1992).|
|94||Wan, et al., "Plasticizers and their effects on microencapsulation process by spray-drying in an aqueous system," J. Microencapsul. 9(1):53-62 (1992).|
|95||Waugh, "Stability compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers, "Am. J Hosp Pharm 48(7):1520-4 (1991).|
|96||Waugh, "Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injected diluted in infusion solutions and stored in various containers," Am. J. Hosp. Pharm. 58(7):1520-24 (1991).|
|97||Westerberg, et al., "Physicochemical aspects of drug release. IV. The effect of carrier particle properties on the dissolution rate from ordered mixtures," Int. J. Pharm. 28:23-31 (1986).|
|98||Yamaoka, et al., "Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration," J. Pharm. Pharmacol. 47(479-86 (1995).|
|99||Yamaoka, et al., "Fate of water-soluble polymers administered via different routes," J. Pharm. Sci. 84(3):349-54 (1995).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8569357||Feb 18, 2011||Oct 29, 2013||Teikoku Pharma Usa, Inc.||Taxane pro-emulsion formulations and methods making and using the same|
|US8821938||Feb 8, 2011||Sep 2, 2014||Acusphere, Inc.||Porous drug matrices and methods of manufacture thereof|
|US8940786||Sep 30, 2013||Jan 27, 2015||Teikoku Pharma Usa, Inc.||Non-aqueous taxane nanodispersion formulations and methods of using the same|
|US9308195||Dec 9, 2014||Apr 12, 2016||Teikoku Pharma Usa, Inc.||Non-aqueous taxane formulations and methods of using the same|
|US20110129533 *||Feb 8, 2011||Jun 2, 2011||Acusphere, Inc.||Porous drug matrices and methods of manufacture thereof|
|US20110207803 *||Feb 18, 2011||Aug 25, 2011||Kiichiro Nabeta||Taxane Pro-Emulsion Formulations and Methods Making and Using the Same|
|U.S. Classification||424/489, 514/449, 424/484, 424/428, 514/951, 549/512, 424/422|
|International Classification||A61K9/14, A61F2/00, A61K9/16, A61K9/70|
|Cooperative Classification||Y10S977/906, A61K9/1611, A61K9/1694, A61K9/1635, A61K9/1623|
|European Classification||A61K9/16H4B, A61K9/16H6B, A61K9/16H2, A61K9/16P4|
|Nov 3, 2008||AS||Assignment|
Owner name: CEPHALON, INC., PENNSYLVANIA
Free format text: SECURITY AGREEMENT;ASSIGNOR:ACUSPHERE, INC.;REEL/FRAME:021773/0477
Effective date: 20081103
|Jul 15, 2010||AS||Assignment|
Owner name: BURRILL LIFE SCIENCES CAPITAL FUND III, L.P., CALI
Free format text: SECURITY AGREEMENT;ASSIGNOR:ACUSPHERE, INC.;REEL/FRAME:024686/0670
Effective date: 20100630
|Feb 15, 2011||FPAY||Fee payment|
Year of fee payment: 8
|Jan 6, 2015||FPAY||Fee payment|
Year of fee payment: 12